Seelos Therapeutics Inc (SEELQ)
Seelos Therapeutics Inc. is a common stock listing on OTC Markets tied to a clinical-stage biopharmaceutical company focused on developing and seeking to commercialize therapies for central nervous system disorders and other conditions. Its pipeline includes SLS-002, an intranasal racemic ketamine program for acute suicidal ideation and behavior in patients with major depressive disorders, as well as SLS-004, SLS-005, SLS-007, and SLS-009, which target neurological and related diseases including Parkinson disease, amyotrophic lateral sclerosis, Sanfilippo syndrome, and Alzheimer disease. The company was founded in 2016 and is based in New York, New York. On November 16, 2024, Seelos Therapeutics filed a voluntary Chapter 11 reorganization petition in the U.S. Bankruptcy Court for the Southern District of New York.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Market Cap |
|---|---|---|---|---|---|---|
|
OTC-SEEL.Q
|
Not available
|
Not available
|
Not available
|
Weak
|
0.0%
|
0.136 K
|
